The IDO1 Knockout PaTu 8988t Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the human pancreatic ductal adenocarcinoma (PDAC) cell line PaTu 8988t. This product provides a heterogeneous pool with targeted disruption of the IDO1 gene, enabling loss-of-function studies in a relevant PDAC model. The polyclonal format reflects diverse editing events, minimizing clonal selection artifacts.
The parental PaTu 8988t cell line is a well-characterized model for PDAC, established from a liver metastasis. It carries KRAS G12V and TP53 R273H mutations, representing common oncogenic drivers in pancreatic cancer. The liver metastasis derivation makes it particularly suitable for studying metastatic behavior and tumor?Chost interactions within the hepatic microenvironment, providing a genetically defined background for IDO1 functional studies.
IDO1 is the rate-limiting enzyme of the kynurenine pathway, catalyzing tryptophan conversion to N-formylkynurenine. Its expression is strongly induced by IFN-?? through the JAK1/JAK2?CSTAT1 axis, as well as by IL-1?? and TNF-??. Downstream, IDO1 activity leads to local tryptophan depletion and build-up of kynurenines, which activate the stress kinase GCN2, resulting in eIF2?? phosphorylation and mTORC1 suppression. Kynurenines also serve as ligands for the aryl hydrocarbon receptor (AhR), promoting regulatory T cell differentiation and immune tolerance. IDO1 enzymatic function requires heme as a cofactor, and is regulated by interactions with BIN1 and SOCS3. Collectively, IDO1 integrates inflammatory signals into a metabolic program that dampens anti-tumor immunity.
In pancreatic ductal adenocarcinoma, IDO1 is frequently overexpressed, correlating with metastasis and immunosuppression. The PaTu 8988t line, originating from a liver metastasis, may exploit IDO1 to evade immune surveillance in the liver milieu. Disrupting IDO1 in this context allows researchers to dissect its role in tumor-intrinsic signaling, such as modulation of mTORC1 and stress responses, and in paracrine effects on immune cells. This model is valuable for exploring how IDO1 cross-talks with KRAS and TP53 mutations, and whether its loss enhances sensitivity to standard-of-care chemotherapeutics or targeted inhibitors.
These polyclonal knockout cells support a broad range of experimental applications. IDO1 disruption can be confirmed by Western blotting and RT-qPCR, while functional validation is achieved via kynurenine production assays. Co-culture with T cells or myeloid populations, followed by flow cytometry for proliferation and suppression markers, enables direct immune readouts. Immunofluorescence and metabolomic profiling of tryptophan/kynurenine levels further characterize the knockout phenotype. The model is ideal for testing IDO1 inhibitors, investigating combination therapies with immune checkpoint blockers, and studying metabolic immune regulation in PDAC. For technical assistance, please contact Ascent Research.
